Incyte Corporation (INCY) fair value analysis

S&P 500 & Nasdaq · Updated 2026-09-07

Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes medicines focused on oncology, inflammation, and other therapeutic areas. The company operates globally with a presence across multiple regions including North America, Europe, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, INCY is trading at a 10–25% discount to estimated fair value.

INCY currently ranks #37 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $126.75
Sector: Healthcare
12-month range: $93.48–$125.01

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Stable
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for INCY

Our model validated 17 trailing price-to-earnings windows for INCY, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $93.48–$125.01.
The 14-day relative strength index sits at a neutral 59.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for INCY
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent INCY news

TickrTrends' derived news-sentiment signal for INCY is currently mixed, computed from recent coverage.

Incyte: Solid Strategies For Continued Growth, But A Possible Pullback Looms (NASDAQ:INCY) (seekingalpha.com, 2026-09-08)
TickrTrends take: Incyte operates in the Healthcare sector where solid execution on growth strategies can support sustained investor interest, yet TickrTrends' current undervalued assessment suggests the stock may offer limited upside cushion if near-term headwinds materialize. A valuation-focused reader should monitor whether the company can demonstrate that its growth initiatives justify current pricing or whether a pullback would bring valuations to even more attractive levels. The gap between TickrTrends' undervalued rating and analyst concerns about potential weakness represents a key tension to watch as earnings and pipeline developments unfold.
Incyte Corporation: Why Jakafi Is No Longer The Real Story Here (NASDAQ:INCY) (seekingalpha.com, 2026-09-02)
TickrTrends take: Incyte operates in the Healthcare sector and is currently assessed as undervalued by TickrTrends. The headline suggests that Jakafi, historically a key revenue driver for the company, is becoming less central to the investment thesis, which indicates that investors focused on valuation should monitor what new developments or product areas might be replacing this established drug's importance to the company's financial performance. Understanding this shift in business focus is relevant to evaluating whether the current undervalued assessment properly reflects the company's evolving revenue sources and growth prospects.

What people are saying

Follow the INCY conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for INCY show a notable change this week, with momentum shifting from a rating of A to none. The stock remains in the Undervalued category based on current valuation metrics.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is INCY stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), INCY is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is INCY's TickrTrends verdict?

INCY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does INCY compare to other Healthcare stocks?

INCY ranks #37 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is INCY overbought or oversold?

INCY's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

INCY vs ABT · INCY vs CI · INCY vs DVA · INCY vs LMAT · INCY vs MMSI